The Filing Desk

Acadia Pharmaceuticals vs Aspire-Lakewood

Acadia Pharmaceuticals ACAD · Aspire-Lakewood ASBP · Pharmaceuticals

Acadia Pharmaceuticals had an operating margin of 9.8%, against -312017.0% at Aspire-Lakewood.

Side by side

Acadia PharmaceuticalsAspire-Lakewood
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.1B$0M
Revenue growth11.9%—
Revenue growth a year, last 5 years19.4%—
Gross margin91.7%−1.9%
Operating margin9.8%−312,017.0%
Net margin36.5%−394,725.1%
Free cash flow$105M—
Free cash flow margin9.8%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.1%116.7%
Last close$17.59$7.65
P/E at the last close8.3×—
Insider trades, last 12 monthssold $2.5 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Acadia PharmaceuticalsAspire-Lakewood
Operating margin
Percent of revenue
Acadia PharmaceuticalsAspire-Lakewood
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Acadia PharmaceuticalsAspire-Lakewood

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Acadia Pharmaceuticals and Aspire-Lakewood pages.